摘要
目的 探讨p53、nm2 3基因在前列腺癌中的表达水平及肿瘤生物学行为和预后关系。方法 应用免疫组化S -P法对 33例前列腺癌和 1 8例前列腺增生症进行p53蛋白、nm2 3蛋白检测。结果 1 5例 (45 .5 % )前列腺癌呈p53蛋白阳性表达 ,前列腺增生症中p53蛋白无阳性表达。 2 4例 (72 .7% )前列腺癌和 1 6例 (88.9% )前列腺增生症呈nm2 3蛋白阳性表达。p53蛋白表达与前列腺癌的分化程度、肿瘤转移及 5年生存率密切相关 ,而与临床分期和复发无关。nm2 3蛋白阳性表达与前列腺癌临床分期、分化程度、肿瘤转移、复发及 5年生存率有关。结论 p53蛋白、nm2 3蛋白表达可作为临床判断前列腺癌预后的重要参考指标。
Objective To explore the expression levels of p53 and nm23 geness in prostate carcinoma and their association with the tumor biological behavior and prognosis. Methods p53 and nm23 protein expressions were detected in paraffin embedded specimens from 33 cases of prostate carcinoma and 18 cases of benign prostatic hyperplasias (BPH) by immunohistochemistry S-P method. Results Positive expression of protein p53 occurred in 15 (45%) cases of prostate carcinoma, while no positive expression was found in BPH patients. Positive expression of protein nm23 was revealed in 24 (72.7%) cases of prostate carcinoma and in 16 (88.9%) cases of BPH. The positive rate of protein 23nm was related to tumor differentiation, carcinoma metastasis and five-year survival rate of prostate carcinoma, but was not associated with clinical staging or relapse. The positive rate of protein m23 was related to clinical staging, tumor differentiation, carcinoma metastasis, relapse and five-year survival rate of protein carcinoma. Conclusion The expression of protein p53 and nm23 can be regarded as indicators for prognosis of prostate carcinoma.
出处
《中国煤炭工业医学杂志》
2002年第4期325-326,共2页
Chinese Journal of Coal Industry Medicine
